Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | SDCBP | O00560 | 9/20 | 0.47 |
| ▸ | SDC2 | P34741 | 9/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18765855 | 1.00 | ALOX15 (0.51) | ALOX15MAPTSMN1; SMN2KDM4ESDCBP | |
| SCHEMBL18765805 | 0.88 | ALOX15 (0.50) | ALOX15MAPTSMN1; SMN2KDM4ESDCBP | |
| SCHEMBL18765807 | 0.88 | ALOX15 (0.50) | ALOX15MAPTSMN1; SMN2KDM4ESDCBP | |
| SCHEMBL18793915 | 0.86 | NPC1 (0.53) | ALOX15MAPTSMN1; SMN2KDM4ESDCBP | |
| SCHEMBL18793911 | 0.86 | NPC1 (0.53) | ALOX15MAPTSMN1; SMN2KDM4ESDCBP | |
| SCHEMBL2180875 | 0.85 | SDCBP (0.51) | ALOX15MAPTSMN1; SMN2KDM4ESDCBP | |
| SCHEMBL2181188 | 0.84 | ALOX15 (0.47) | ALOX15MAPTSMN1; SMN2KDM4ESDCBP | |
| SCHEMBL18765599 | 0.82 | SDCBP (0.52) | ALOX15MAPTSMN1; SMN2KDM4ESDCBP | |
| SCHEMBL2179112 | 0.82 | SDCBP (0.52) | ALOX15MAPTSMN1; SMN2KDM4ESDCBP | |
| SCHEMBL18765504 | 0.82 | SDCBP (0.52) | ALOX15MAPTSMN1; SMN2KDM4ESDCBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-12030873-B2 | 6-pyrimidin-isoindole derivative as ERK1/2 inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-07-09 | — | — | US | disclosed |
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-26 | — | — | US | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| CN-114948963-A | Protein kinase inhibitor benzolactam compounds | 大冢制药株式会社 | 2022-08-30 | — | — | CN | disclosed |
| US-20220169638-A1 | 6-PYRIMIDIN-ISOINDOLE DERIVATIVE AS ERK1/2 INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-06-02 | — | — | US | disclosed |
| CN-108617166-B | Protein kinase inhibitor benzolactam compounds | 大冢制药株式会社 | 2022-05-17 | — | — | CN | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| EP-3612524-A1 | 6-PYRIMIDIN-ISOINDOLE DERIVATIVE AS ERK1/2 INHIBITOR | Otsuka Pharmaceutical Co., Ltd. (JP) | 2020-02-26 | — | — | EP | disclosed |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-29 | — | — | US | disclosed |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-14 | — | — | US | disclosed |
| WO-2018193410-A1 | 6-PYRIMIDIN-ISOINDOLE DERIVATIVE AS ERK1/2 INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-10-25 | — | — | WO | disclosed |
| EP-3365334-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2018-08-29 | — | — | EP | disclosed |
| WO-2017068412-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | ALOX15 1370/4885MAPT 458/4885SMN1; SMN2 2550/4885 |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | ALOX15 1370/4885MAPT 458/4885SMN1; SMN2 2550/4885 |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | ALOX15 1370/4885MAPT 458/4885SMN1; SMN2 2550/4885 |
| US-12030873-B2 | 6-pyrimidin-isoindole derivative as ERK1/2 inhibitor | MAPKAPK2, MAP4K2, MAPK1 | ALOX15 4598/4885MAPT 1053/4885SMN1; SMN2 1081/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | ALOX15 1166/4885MAPT 476/4885SMN1; SMN2 2671/4885 |
| US-20220169638-A1 | 6-PYRIMIDIN-ISOINDOLE DERIVATIVE AS ERK1/2 INHIBITOR | MAPKAPK2, MAP4K2, MAPK1 | ALOX15 4598/4885MAPT 1053/4885SMN1; SMN2 1081/4885 |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | ALOX15 1370/4885MAPT 458/4885SMN1; SMN2 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.